Psilocybin Clinical Trial Hits NYSE
LaunchPad is your place to discover, understand, and stay up-to-date with early stage public companies.
Welcome to LaunchPad. Your place to discover, understand, and stay up-to-date with early stage public companies.
NYSE Listed Psychedelic Company Begins Clinical Trial Dosing
Cybin (NYSE: CYBN) has officially begun dosing its first patients in their Phase I/2a clinical trial of psilocybin for Major Depressive Disorder.
Their novel molecule CYB003 is aiming to unlock the therapeutic benefits of oral psilocybin, while having a faster onset and shorter duration of effect for patients.
The clinical trial consists of two separate doses of CYB003, one in the third week and one in the sixth week, and will measure patients experience over a total of twelve weeks.
- Enthusiast Gaming (NASDAQ:EGLX) partnered with the National Football League to launch NFL Tuesday Night Gaming.
- Hempacco (NASDAQ:HPCO) raised $6M USD in their Nasdaq IPO. Shares debuted at six times the IPO price.
- Verses Technology (NEO: VERS) closed $14.97M CAD in new funding to expand their AI technologies.
- Brainsway, a Jerusalem-based developer of magnetic device treatments for OCD, will raise $30M USD in a Nasdaq IPO.
LaunchPad is owned by Bolt Media. To learn more about opportunities to position your brand or company in front of Bolt's 100,000+ community members, reach out here.